{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:07:50Z","timestamp":1795172870163,"version":"4.10.3"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["PFR-6"],"award-info":[{"award-number":["PFR-6"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["DARRI\/CARNOT Maturation program"],"award-info":[{"award-number":["DARRI\/CARNOT Maturation program"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["DARRI\/CARNOT Maturation program"],"award-info":[{"award-number":["DARRI\/CARNOT Maturation program"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["PFR-4"],"award-info":[{"award-number":["PFR-4"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["PFR-6"],"award-info":[{"award-number":["PFR-6"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["DARRI\/CARNOT"],"award-info":[{"award-number":["DARRI\/CARNOT"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["DARRI\/CARNOT"],"award-info":[{"award-number":["DARRI\/CARNOT"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["PFR-6"],"award-info":[{"award-number":["PFR-6"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","award":["PFR-6"],"award-info":[{"award-number":["PFR-6"]}],"id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-77"],"award-info":[{"award-number":["ANR-10-LABX-77"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["LABX Milieu Interieur"],"award-info":[{"award-number":["LABX Milieu Interieur"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-77"],"award-info":[{"award-number":["ANR-10-LABX-77"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR\/FFRM Flash covid"],"award-info":[{"award-number":["ANR\/FFRM Flash covid"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR coronamito"],"award-info":[{"award-number":["ANR coronamito"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Minist\u00e8re de l'Enseignement Sup\u00e9rieur et de la Recherche\/Ecole Doctorale BIOSPC, Universit\u00e9 Paris cit\u00e9"},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["Emergen program"],"award-info":[{"award-number":["Emergen program"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["Emergen"],"award-info":[{"award-number":["Emergen"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HERA europeen funding IDISCOVR"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The continuous emergence of antibody-escape variants of SARS-CoV-2 demands the identification of alternative methods of protection against infection that do not directly target viral proteins. Here, we generated heavy-chain-only antibody (VHHs) from an alpaca immunized with the human angiotensin-converting enzyme 2 (hACE2), the major entry receptor for SARS-CoV-2. The VHHs bind hACE2 without affecting its enzymatic activity, and two of them (B07 and B09) inhibit all SARS-CoV-2 isolates tested (Delta, BA.1, BQ1.1, XBB.1.5, XBB.1.16.1, EG.5.1.3, BA.2.86.1). Their X-ray structure in complex with hACE2 show that their epitope overlaps with the footprint of the receptor binding domain (RBD) of the SARS-CoV-2 spike on hACE2. A dimeric B07-Fc fusion construct avidly binds hACE2 with an apparent dissociation constant of 0.1\u2009nM and inhibits in vitro infection of previously tested variants and, of JN.1.1 and KP.3.3 variants, with an IC50\u2009~\u20091\u2009nM. In vivo experiments using K18-hACE2 mice show that intranasal prophylactic administration of B07-Fc confer a dose-dependent protection against SARS-CoV-2 D614G and Omicron variants. These VHHs targeting hACE2 represent potential broad-spectrum therapeutic candidates against potential new emerging coronaviruses using hACE2 as a receptor.<\/jats:p>","DOI":"10.1038\/s41467-025-65144-w","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:59:19Z","timestamp":1763729959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting ACE2 with a camelid antibody inhibits SARS-CoV-2 binding and has protective effects in vivo"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8438-5555","authenticated-orcid":false,"given":"Simon","family":"Blachier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-9988","authenticated-orcid":false,"given":"Marie-Christine","family":"Vaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Conquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0028-1944","authenticated-orcid":false,"given":"Emilie","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atousa","family":"Arbabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7025-4343","authenticated-orcid":false,"given":"Vincent","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0820-6277","authenticated-orcid":false,"given":"Fruzsina","family":"Szilagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Guez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Boucharlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Chiaravalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaouen","family":"Tran-Rajau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Haouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Petres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-9954","authenticated-orcid":false,"given":"Delphine","family":"Planas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9372-5398","authenticated-orcid":false,"given":"Xavier","family":"Montagutelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6280-239X","authenticated-orcid":false,"given":"Fabrice","family":"Agou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-1342","authenticated-orcid":false,"given":"Pierre","family":"Lafaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0438-8095","authenticated-orcid":false,"given":"Gabriel","family":"Ayme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-1475","authenticated-orcid":false,"given":"Olivier","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-7988","authenticated-orcid":false,"given":"Felix A.","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-349X","authenticated-orcid":false,"given":"Jost","family":"Enninga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-4909","authenticated-orcid":false,"given":"Anne","family":"Brelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"65144_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med"},{"key":"65144_CR2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"65144_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med"},{"key":"65144_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2025.110508","volume":"607","author":"C Chakraborty","year":"2025","unstructured":"Chakraborty, C., Bhattacharya, M. & Abdelhameed, A. S. Recent SARS-CoV-2 evolution trajectories indicate the emergence of Omicron\u2019s several subvariants and the current rise of KP.3.1.1 and XEC. Virology 607, 110508 (2025).","journal-title":"Virology"},{"key":"65144_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46490-7","volume":"15","author":"D Planas","year":"2024","unstructured":"Planas, D. et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun. 15, 2254 (2024).","journal-title":"Nat. Commun."},{"key":"65144_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","volume":"637","author":"F Jian","year":"2025","unstructured":"Jian, F. et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature 637, 921\u2013929 (2025).","journal-title":"Nature"},{"key":"65144_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v10i1.752","volume":"10","author":"D Planas","year":"2024","unstructured":"Planas, D. et al. Escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP3.3 from approved monoclonal antibodies. Pathog. Immun. 10, 1\u201311 (2024).","journal-title":"Pathog. Immun."},{"key":"65144_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115543","volume":"44","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC. Cell Rep. 44, 115543 (2025).","journal-title":"Cell Rep."},{"key":"65144_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01156-3","volume":"10","author":"LA Bruno","year":"2025","unstructured":"Bruno, L. A. et al. Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity. NPJ Vaccines 10, 108 (2025).","journal-title":"NPJ Vaccines"},{"key":"65144_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59344-7","volume":"16","author":"HJ Appaneal","year":"2025","unstructured":"Appaneal, H. J. et al. Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US veterans affairs healthcare system. Nat. Commun. 16, 4033 (2025).","journal-title":"Nat. Commun."},{"key":"65144_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq5720","volume":"17","author":"AA Rubio","year":"2025","unstructured":"Rubio, A. A. et al. Bispecific antibodies targeting the N-terminal and receptor binding domains potently neutralize SARS-CoV-2 variants of concern. Sci. Transl. Med. 17, eadq5720 (2025).","journal-title":"Sci. Transl. Med."},{"key":"65144_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e278 (2020).","journal-title":"Cell"},{"key":"65144_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-020-00662-x","volume":"9","author":"MY Li","year":"2020","unstructured":"Li, M. Y., Li, L., Zhang, Y. & Wang, X. S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Poverty 9, 45 (2020).","journal-title":"Infect. Dis. Poverty"},{"key":"65144_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jacc.2008.04.059","volume":"52","author":"B Greenberg","year":"2008","unstructured":"Greenberg, B. An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling. J. Am. Coll. Cardiol. 52, 755\u2013757 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"65144_CR15","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","volume":"280","author":"DW Lambert","year":"2005","unstructured":"Lambert, D. W. et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 280, 30113\u201330119 (2005).","journal-title":"J. Biol. Chem."},{"key":"65144_CR16","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.cell.2021.02.053","volume":"184","author":"ML Yeung","year":"2021","unstructured":"Yeung, M. L. et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell 184, 2212\u20132228.e2212 (2021).","journal-title":"Cell"},{"key":"65144_CR17","doi-asserted-by":"crossref","unstructured":"Ameratunga, R. et al. Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19. Clin. Exp. Immunol. 214, 289\u2212295 (2023).","DOI":"10.1093\/cei\/uxad096"},{"key":"65144_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24013-y","volume":"12","author":"Y Higuchi","year":"2021","unstructured":"Higuchi, Y. et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun. 12, 3802 (2021).","journal-title":"Nat. Commun."},{"key":"65144_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2623","volume":"15","author":"E Urano","year":"2023","unstructured":"Urano, E. et al. An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models. Sci. Transl. Med 15, eadi2623 (2023).","journal-title":"Sci. Transl. Med"},{"key":"65144_CR20","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"65144_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25331-x","volume":"12","author":"Y Du","year":"2021","unstructured":"Du, Y. et al. A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants. Nat. Commun. 12, 5000 (2021).","journal-title":"Nat. Commun."},{"key":"65144_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41564-023-01389-9","volume":"8","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies. Nat. Microbiol. 8, 1051\u20131063 (2023).","journal-title":"Nat. Microbiol."},{"key":"65144_CR23","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1016\/j.ymthe.2023.09.002","volume":"31","author":"CP Sun","year":"2023","unstructured":"Sun, C. P. et al. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants. Mol. Ther. 31, 3322\u20133336 (2023).","journal-title":"Mol. Ther."},{"key":"65144_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-021-00740-y","volume":"6","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. Signal Transduct. Target Ther. 6, 315 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"65144_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2404166","volume":"13","author":"M Li","year":"2024","unstructured":"Li, M. et al. Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes. Emerg. Microbes Infect. 13, 2404166 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"65144_CR26","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu, Y., Jiang, S. & Ying, T. Single-domain antibodies as therapeutics against human viral diseases. Front Immunol. 8, 1802 (2017).","journal-title":"Front Immunol."},{"key":"65144_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/toxins11080464","volume":"11","author":"SA Godakova","year":"2019","unstructured":"Godakova, S. A. et al. Camelid VHHs fused to human FC fragments provide long term protection against botulinum neurotoxin A in mice. Toxins (Basel) 11, 464 (2019).","journal-title":"Toxins (Basel)"},{"key":"65144_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.canlet.2009.08.003","volume":"289","author":"A Bell","year":"2010","unstructured":"Bell, A. et al. Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett. 289, 81\u201390 (2010).","journal-title":"Cancer Lett."},{"key":"65144_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.nucmedbio.2015.03.003","volume":"42","author":"M Rotman","year":"2015","unstructured":"Rotman, M. et al. Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP\/PS1 mice but does not increase brain uptake. Nucl. Med. Biol. 42, 695\u2013702 (2015).","journal-title":"Nucl. Med. Biol."},{"key":"65144_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully, M. et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N. Engl. J. Med. 380, 335\u2013346 (2019).","journal-title":"N. Engl. J. Med."},{"key":"65144_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021107985","volume":"40","author":"T Guttler","year":"2021","unstructured":"Guttler, T. et al. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. EMBO J. 40, e107985 (2021).","journal-title":"EMBO J."},{"key":"65144_CR32","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106267","volume":"39","author":"J Buchrieser","year":"2020","unstructured":"Buchrieser, J. et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 39, e106267 (2020).","journal-title":"EMBO J."},{"key":"65144_CR33","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1124\/mol.104.008565","volume":"67","author":"C Watson","year":"2005","unstructured":"Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharm. 67, 1268\u20131282 (2005).","journal-title":"Mol. Pharm."},{"key":"65144_CR34","doi-asserted-by":"crossref","unstructured":"Wang, N. et al. A MERS-CoV-like mink coronavirus uses ACE2 as entry receptor. Nature 642, 739\u2013746 (2025).","DOI":"10.1038\/s41586-025-09007-w"},{"key":"65144_CR35","doi-asserted-by":"publisher","first-page":"19970","DOI":"10.1073\/pnas.0908837106","volume":"106","author":"K Wu","year":"2009","unstructured":"Wu, K., Li, W., Peng, G. & Li, F. Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor. Proc. Natl. Acad. Sci. USA 106, 19970\u201319974 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65144_CR36","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","volume":"103","author":"GA Lazar","year":"2006","unstructured":"Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103, 4005\u20134010 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65144_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01351-23","volume":"98","author":"W Bolland","year":"2024","unstructured":"Bolland, W. et al. High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1. J. Virol. 98, e0135123 (2024).","journal-title":"J. Virol."},{"key":"65144_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19145-6","volume":"11","author":"IT Lee","year":"2020","unstructured":"Lee, I. T. et al. ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat. Commun. 11, 5453 (2020).","journal-title":"Nat. Commun."},{"key":"65144_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cell.2022.11.030","volume":"186","author":"CT Wu","year":"2023","unstructured":"Wu, C. T. et al. SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming. Cell 186, 112\u2013130 e120 (2023).","journal-title":"Cell"},{"key":"65144_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36561-6","volume":"14","author":"D Planas","year":"2023","unstructured":"Planas, D. et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat. Commun. 14, 824 (2023).","journal-title":"Nat. Commun."},{"key":"65144_CR41","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/jmv.25832","volume":"92","author":"M Hussain","year":"2020","unstructured":"Hussain, M. et al. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J. Med Virol. 92, 1580\u20131586 (2020).","journal-title":"J. Med Virol."},{"key":"65144_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"65144_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/v16010081","volume":"16","author":"MJ Jahid","year":"2024","unstructured":"Jahid, M. J., Bowman, A. S. & Nolting, J. M. SARS-CoV-2 outbreaks on mink farms-a review of current knowledge on virus infection, spread, spillover, and containment. Viruses 16, 81 (2024).","journal-title":"Viruses"},{"key":"65144_CR44","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00018-023-04779-8","volume":"80","author":"Q Li","year":"2023","unstructured":"Li, Q. et al. Generation of nanobodies acting as silent and positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. Cell Mol. Life Sci. 80, 164 (2023).","journal-title":"Cell Mol. Life Sci."},{"key":"65144_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105259","volume":"25","author":"P Pymm","year":"2022","unstructured":"Pymm, P. et al. Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2. iScience 25, 105259 (2022).","journal-title":"iScience"},{"key":"65144_CR46","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41587-020-0577-1","volume":"38","author":"N Eroshenko","year":"2020","unstructured":"Eroshenko, N. et al. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat. Biotechnol. 38, 789\u2013791 (2020).","journal-title":"Nat. Biotechnol."},{"key":"65144_CR47","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cell.2021.02.035","volume":"184","author":"E Andreano","year":"2021","unstructured":"Andreano, E. et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell 184, 1821\u20131835.e1816 (2021).","journal-title":"Cell"},{"key":"65144_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11537830-000000000-00000","volume":"25","author":"E Kaneko","year":"2011","unstructured":"Kaneko, E. & Niwa, R. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs 25, 1\u201311 (2011).","journal-title":"BioDrugs"},{"key":"65144_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0167-4838(99)00030-8","volume":"1431","author":"RH van der Linden","year":"1999","unstructured":"van der Linden, R. H. et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys. Acta 1431, 37\u201346 (1999).","journal-title":"Biochim Biophys. Acta"},{"key":"65144_CR50","doi-asserted-by":"publisher","first-page":"e1009542","DOI":"10.1371\/journal.ppat.1009542","volume":"17","author":"K Haga","year":"2021","unstructured":"Haga, K. et al. Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model. PLoS Pathog. 17, e1009542 (2021).","journal-title":"PLoS Pathog."},{"key":"65144_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17425247.2024.2446608","volume":"22","author":"N Alphonse","year":"2025","unstructured":"Alphonse, N., Secher, T. & Heuze-Vourc\u2019h, N. A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview. Expert Opin. Drug Deliv. 22, 197\u2013218 (2025).","journal-title":"Expert Opin. Drug Deliv."},{"key":"65144_CR52","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl. Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65144_CR53","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"65144_CR54","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/infdis\/jiab289","volume":"223","author":"BL Haagmans","year":"2021","unstructured":"Haagmans, B. L. et al. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model. J. Infect. Dis. 223, 2020\u20132028 (2021).","journal-title":"J. Infect. Dis."},{"key":"65144_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2260040","volume":"19","author":"D Focosi","year":"2023","unstructured":"Focosi, D. & Maggi, F. Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy. Hum. Vaccin Immunother. 19, 2260040 (2023).","journal-title":"Hum. Vaccin Immunother."},{"key":"65144_CR56","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2047144","volume":"14","author":"TJ Esparza","year":"2022","unstructured":"Esparza, T. J. et al. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19. MAbs 14, 2047144 (2022).","journal-title":"MAbs"},{"key":"65144_CR57","doi-asserted-by":"publisher","first-page":"eabh0319","DOI":"10.1126\/sciadv.abh0319","volume":"7","author":"S Nambulli","year":"2021","unstructured":"Nambulli, S. et al. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci. Adv. 7, eabh0319 (2021).","journal-title":"Sci. Adv."},{"key":"65144_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/v16020185","volume":"16","author":"MF Pavan","year":"2024","unstructured":"Pavan, M. F. et al. SARS-CoV-2 specific nanobodies neutralize different variants of concern and reduce virus load in the brain of h-ACE2 transgenic mice. Viruses 16, 185 (2024).","journal-title":"Viruses"},{"key":"65144_CR59","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.chembiol.2021.06.008","volume":"29","author":"E Cecon","year":"2022","unstructured":"Cecon, E. et al. SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem. Biol. 29, 74\u201383.e74 (2022).","journal-title":"Cell Chem. Biol."},{"key":"65144_CR60","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","volume":"27","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917\u2013924 (2021).","journal-title":"Nat. Med."},{"key":"65144_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100850","volume":"3","author":"T Bruel","year":"2022","unstructured":"Bruel, T. et al. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. Cell Rep. Med. 3, 100850 (2022).","journal-title":"Cell Rep. Med."},{"key":"65144_CR62","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.medj.2023.07.007","volume":"4","author":"T Bruel","year":"2023","unstructured":"Bruel, T. et al. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients. Med. 4, 664\u2013667 (2023).","journal-title":"Med."},{"key":"65144_CR63","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.molimm.2008.09.008","volume":"46","author":"P Lafaye","year":"2009","unstructured":"Lafaye, P., Achour, I., England, P., Duyckaerts, C. & Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 46, 695\u2013704 (2009).","journal-title":"Mol. Immunol."},{"key":"65144_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-9-14","volume":"9","author":"S Moutel","year":"2009","unstructured":"Moutel, S. et al. A multi-Fc-species system for recombinant antibody production. BMC Biotechnol. 9, 14 (2009).","journal-title":"BMC Biotechnol."},{"key":"65144_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ab.2007.08.017","volume":"373","author":"RL Rich","year":"2008","unstructured":"Rich, R. L. et al. Extracting kinetic rate constants from surface plasmon resonance array systems. Anal. Biochem. 373, 112\u2013120 (2008).","journal-title":"Anal. Biochem."},{"key":"65144_CR66","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.immuni.2021.09.011","volume":"54","author":"A Sokal","year":"2021","unstructured":"Sokal, A. et al. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54, 2893\u20132907.e2895 (2021).","journal-title":"Immunity"},{"key":"65144_CR67","doi-asserted-by":"publisher","first-page":"e20220638","DOI":"10.1084\/jem.20220638","volume":"219","author":"C Planchais","year":"2022","unstructured":"Planchais, C. et al. Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. J. Exp. Med. 219, e20220638 (2022).","journal-title":"J. Exp. Med."},{"key":"65144_CR68","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2022","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2022).","journal-title":"Nature"},{"key":"65144_CR69","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.3390\/molecules24244451","volume":"24","author":"P Weber","year":"2019","unstructured":"Weber, P. et al. High-throughput crystallization pipeline at the crystallography core facility of the institut pasteur. Molecules 24, 4451 (2019).","journal-title":"Molecules"},{"key":"65144_CR70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1107\/S0907444909047374","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. D. Biol. Crystallogr. 66, 133\u2013144 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"65144_CR71","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution?. Acta Crystallogr. D. Biol. Crystallogr. 69, 1204\u20131214 (2013).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"65144_CR72","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.sbi.2015.07.003","volume":"34","author":"PA Karplus","year":"2015","unstructured":"Karplus, P. A. & Diederichs, K. Assessing and maximizing data quality in macromolecular crystallography. Curr. Opin. Struct. Biol. 34, 60\u201368 (2015).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"65144_CR73","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"65144_CR74","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"65144_CR75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"65144_CR76","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1107\/S0907444900014736","volume":"57","author":"MD Winn","year":"2001","unstructured":"Winn, M. D., Isupov, M. N. & Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta. Crystallogr. D. Biol. Crystallogr. 57, 122\u2013133 (2001).","journal-title":"Acta. Crystallogr. D. Biol. Crystallogr."},{"key":"65144_CR77","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1107\/S0907444904016427","volume":"60","author":"E Blanc","year":"2004","unstructured":"Blanc, E. et al. Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta. Crystallogr. D. Biol. Crystallogr. 60, 2210\u20132221 (2004).","journal-title":"Acta. Crystallogr. D. Biol. Crystallogr."},{"key":"65144_CR78","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams, C. J. et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 27, 293\u2013315 (2018).","journal-title":"Protein Sci."},{"key":"65144_CR79","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u2013797 (2007).","journal-title":"J. Mol. Biol."},{"key":"65144_CR80","doi-asserted-by":"publisher","first-page":"W665","DOI":"10.1093\/nar\/gkh381","volume":"32","author":"TJ Dolinsky","year":"2004","unstructured":"Dolinsky, T. J., Nielsen, J. E., McCammon, J. A. & Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665\u2013W667 (2004).","journal-title":"Nucleic Acids Res."},{"key":"65144_CR81","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.1073\/pnas.181342398","volume":"98","author":"NA Baker","year":"2001","unstructured":"Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & McCammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98, 10037\u201310041 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65144_CR82","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","volume":"22","author":"JD Thompson","year":"1994","unstructured":"Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22, 4673\u20134680 (1994).","journal-title":"Nucleic Acids Res."},{"key":"65144_CR83","doi-asserted-by":"publisher","first-page":"W320","DOI":"10.1093\/nar\/gku316","volume":"42","author":"X Robert","year":"2014","unstructured":"Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320\u2013W324 (2014).","journal-title":"Nucleic Acids Res."},{"key":"65144_CR84","doi-asserted-by":"publisher","first-page":"D1006","DOI":"10.1093\/nar\/gkn838","volume":"37","author":"MP Lefranc","year":"2009","unstructured":"Lefranc, M. P. et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 37, D1006\u2013D1012 (2009).","journal-title":"Nucleic Acids Res."},{"key":"65144_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1084\/jem.132.2.211","volume":"132","author":"TT Wu","year":"1970","unstructured":"Wu, T. T. & Kabat, E. A. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 132, 211\u2013250 (1970).","journal-title":"J. Exp. Med."},{"key":"65144_CR86","doi-asserted-by":"crossref","unstructured":"Saunders, N. et al. TMPRSS2 is a functional receptor for human coronavirus HKU1. Nature 624, 207\u2212214 (2023).","DOI":"10.1038\/s41586-023-06761-7"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65144-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65144-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65144-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T14:03:11Z","timestamp":1763733791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65144-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65144"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65144-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SB, IF, IS, FAR, PL, GA, OS, ABr are designated as inventors in patent application No. WO 2025\/056771 A1 filed by Institut Pasteur. The patent application covers the aspects of anti-ACE2 VHH B07, B09, B10 described in the manuscript. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10268"}}